This incremental transfer of Kazia shares to US interests bodes well, or not so well, depending what may eventually transpire.
If Kazia does what we all want it to do; develop standard-of-care drugs to combat various cancers, then all the vested interests, other than Australian retail shareholders, will be screaming for a reverse-split and a full listing on Nasdaq.
Just look at what is currently happening to that great little medical device company Avita; their "spray-on-skin" technology took 11 years to develop in Australia [Perth] and is now in the process of shifting the whole shabang across to San Diego and the Nasdaq. Sure the burns market in the US is huge and in commercial terms it all makes sense....but it means the Australian shareholders will be left holding Avita CDIs on the ASX.
KZA Price at posting:
37.0¢ Sentiment: Hold Disclosure: Held